| Trial ID: | L0172 |
| Source ID: | NCT02342639
|
| Associated Drug: |
Rifaximin
|
| Title: |
Rifaximin Therapy in Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02342639/results
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: Rifaximin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in Serum Trimethylamine N-oxide (TMAO), Change from baseline to Day 11 | Secondary: C-reactive Protein, Change from baseline to Day 11|Change in Serum Interleukin-6 (IL-6), post- minus pre-treatment values, Change from baseline to day 11
|
| Sponsor/Collaborators: |
Sponsor: Jason Stubbs, MD
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
38
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2015-06
|
| Completion Date: |
2019-03-01
|
| Results First Posted: |
2021-11-05
|
| Last Update Posted: |
2021-11-05
|
| Locations: |
University of Kansas Medical Center, Kansas City, Kansas, 66160, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02342639
|
